{"analyses":[{"ciLowerLimit":"0.468","ciNumSides":"TWO_SIDED","ciPctValue":"98.5","ciUpperLimit":"0.973","estimateComment":"Estimate of the treatment hazard ratio is based on a stratified Cox's Proportional Hazards Model, \\<1 indicates a lower risk with olaparib compared with placebo arm. Stratification factors are the same as those used in the stratified log-rank test.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.0091","pValueComment":"A multiple testing procedure is employed across the primary and all key secondary endpoints to strongly control overall type I error at 5% (2 sided) accounting for all analysis timepoints.","paramType":"Hazard Ratio (HR)","paramValue":"0.678","statisticalComment":"Log rank test is stratified by chemotherapy type, hormone receptor status, and prior platinum therapy using a pre-specified pooling strategy.","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"75"},{"groupId":"OG001","value":"109"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"921"},{"groupId":"OG001","value":"915"}],"units":"Participants"}],"description":"An OS event is defined as death by any cause.","groups":[{"description":"Olaparib tablets 300mg taken orally twice daily.","id":"OG000","title":"Olaparib"},{"description":"Placebo tablets taken orally twice daily.","id":"OG001","title":"Placebo"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Full Analysis Set (FAS)","reportingStatus":"POSTED","timeFrame":"From date of randomisation to data cut off: 12 July 2021 (approximately 7 years 3 months)","title":"Overall Survival (OS)","type":"SECONDARY","unitOfMeasure":"Participants"}